# Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes

> **NCT02948777** · PHASE4 · COMPLETED · sponsor: **Marja-Riitta Taskinen** · enrollment: 14 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT02948777
- **Lead sponsor:** Marja-Riitta Taskinen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02948777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02948777, "Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02948777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*